Skip to main content
sophie-papa

Dr Sophie Papa

Clinical Reader

Research interests

  • Cancer
  • Immunology

Contact details

Biography

Sophie Papa is a Clinical Reader in Immuno-oncology and Consultant Medical Oncologist at King’s College London and Guy’s and St Thomas’ NHS Foundation Trust (GSTT). Sophie undertook her medical training at the University of Oxford and Imperial College London. She completed a PhD in solid tumour CAR T-cell cancer immunotherapy from King’s College London in 2011.

She is a clinical academic with research interests in the field of immune-oncology. Her group have two areas of study: Firstly, strategies to enhance CAR T-cell clinical translation and secondly, cohort based investigation of mechanism of checkpoint inhibitor driven inflammatory disease. Sophie is a medical oncologist with a practice in malignant melanoma and Merkle cell carcinoma. As a principal investigator in the GSTT Early Phase Trials Team Sophie has expertise in the design and delivery of first in man studies. She has a particular focus on building skills and capabilities to deliver immune effector cell therapies for solid tumours. She is the lead for skin cancer research and chairs the biological safety committee.

    Research

    experimental-oncology
    Experimental Oncology

    The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.

    Project status: Ongoing

    Immunology and Immunotherapy Programme Header
    Cancer Immunology & Immunotherapy

    Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.

    Project status: Ongoing

    News

    Trial to repurpose cancer drug for patients with COVID-19 launches

    A new trial repurposing a blood cancer drug for patients with COVID-19 is being launched.

    covid cancer drug

    Study identifies medications safe to use in COVID-19 treatment

    A recent study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19.

    coronavirus ibuprofen

    Sophie Papa recognised as life science trailblazer

    Dr Sophie Papa was recently featured as one of the trailblazers and trendsetters shaping the future of the UK life science sector by BioBeat in their sixth...

    Dr Sophie Papa

      Research

      experimental-oncology
      Experimental Oncology

      The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.

      Project status: Ongoing

      Immunology and Immunotherapy Programme Header
      Cancer Immunology & Immunotherapy

      Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.

      Project status: Ongoing

      News

      Trial to repurpose cancer drug for patients with COVID-19 launches

      A new trial repurposing a blood cancer drug for patients with COVID-19 is being launched.

      covid cancer drug

      Study identifies medications safe to use in COVID-19 treatment

      A recent study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19.

      coronavirus ibuprofen

      Sophie Papa recognised as life science trailblazer

      Dr Sophie Papa was recently featured as one of the trailblazers and trendsetters shaping the future of the UK life science sector by BioBeat in their sixth...

      Dr Sophie Papa